IPR policy under review in India

1 August 2022

Having been retained on the US Trade Representative's (USTR's) Priority Watch List alongside six other countries, the Indian government has undertaken an intellectual property review exercise to assess the risks to innovation and economic growth as posed by the USTR, reports The Pharma Letter’s India correspondent.

The USTR released a report last month that states India continues to be one of the most challenging major economies as far as intellectual property rights (IPR) protection and enforcement is concerned.

The US has placed six other countries - China, Indonesia, Argentina, Russia, Chile and Venezuela - on the Priority Watch List for lacking requisite IPR protection and enforcement, with the report highlighting the problematic Section 3(d) of India's patent law, which does not allow for provision of patents for incremental innovation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK